DNLI241220C17500
- 13.50
- 0.000.00%
Denali Therapeutics Newsroom
B.Riley Financial Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Raises Target Price to $38
BofA Securities Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Raises Target Price to $34
Denali Therapeutics: Promising Pipeline and Strategic Advancements Justify Buy Rating
B.Riley Financial Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Maintains Target Price $33
Denali Therapeutics (DNLI) Receives a Hold From Stifel Nicolaus
Morgan Stanley Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Maintains Target Price $41
TD Cowen Maintains Denali Therapeutics(DNLI.US) With Buy Rating
HC Wainwright & Co. Reiterates Buy on Denali Therapeutics, Maintains $90 Price Target
H.C. Wainwright Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Maintains Target Price $90
TD Cowen Maintains Denali Therapeutics(DNLI.US) With Buy Rating
Promising Developments and Strategic Advancements Propel Denali Therapeutics' Buy Rating
Denali Therapeutics Is Maintained at Buy by Jefferies
Denali Therapeutics Analyst Ratings
Jefferies Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Raises Target Price to $45
BTIG Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Maintains Target Price $35
J.P. Morgan Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Cuts Target Price to $28
JP Morgan Maintains Overweight on Denali Therapeutics, Lowers Price Target to $28
TD Cowen Maintains Denali Therapeutics(DNLI.US) With Buy Rating
Denali Therapeutics (DNLI) Receives a Buy From TD Cowen
Raymond James Initiates Denali Therapeutics(DNLI.US) With Hold Rating